论文部分内容阅读
比较石杉碱甲胶囊和片剂对阿尔采末病的疗效和安全性．方法：采用双盲双模拟法将入选的６０例阿尔采末病人随机等分两组，胶囊组每次口服石杉碱甲胶囊４粒和安慰剂片４片；片剂组每次口服石杉碱甲片（哈伯因）４片和安慰剂胶囊４粒，两组均每日两次，６０日为一疗程．所有病人都测量ＷＭＳ，ＭＭＳ，ＨＤＳ－Ｒ，ＩＡＤＬ，ＧＢＳ痴呆综合征量表和各种检查以及氧自由基．结果：两组所有心理量表值疗后均有显著改善（Ｐ＜０．０１），而两组间无明显差异（Ｐ＞０．０５），且等效检验合格；两组的自由基病理变化疗后也明显减轻，但也无组间差异（Ｐ＞０．０５）；两组未发生严重不良反应．结论：石杉碱甲胶囊和片剂治疗阿尔采末病时疗效和安全性相等。
To compare the efficacy and safety of huperzine A capsules and tablets on Alzheimers disease. Methods: Sixty patients with Alzheimer’s disease were randomly divided into two groups by double-blind double-dummy method. The capsule group received 4 huperzine capsules and 4 placebo tablets at a time. 4 tablets of alkali tablets (Hubble) and 4 capsules of placebo capsules, two groups were twice daily, 60 days for a course of treatment. All patients measured WMS, MMS, HDS-R, IADL, GBS dementia syndrome scales and various examinations as well as oxygen free radicals. Results: All the psychometric scales of both groups were significantly improved after treatment (P <0.01), but there was no significant difference between the two groups (P> 0.05), and the equivalent test was acceptable. The free radical pathology Changes were also significantly reduced after treatment, but no difference between groups (P> 0.05); two groups did not occur serious adverse reactions. Conclusion: Huperzine capsules and tablets are equally effective and safe in the treatment of Alzheimer’s disease.